Jarushka Naidoo: Excellent Talk from Bingnan Zhang on CNS Activity in BiTES and ADCs
Jarushka Naidoo, Full Professor and Consultant Medical Oncologist at Royal College of Surgeons in Irelan, shared a post on X:
“CNS activity in BiTES and ADCs
Excellent talk from Bingnan Zhang, MD Anderson Cancer Center on intracranial response of untreated BM from tarlatamab in SCLC:
– 10 patients (9 BM, 1 LMD)
– icORR 90%
– selected responses rapid
Can we avoid WBRT in these patients?”
Nancy Lin, Breast Cancer Specialist and Director of EMBRACE MBC Program at Dana-Farber Cancer Institute, shared this post, adding:
“We are seeing CNS activity with:
– multiple ADCs (TDXD, HER3-DXD, TDM1, sacituzumab)
– BiTEs (tarlatamab)
– bispecifics (ivonescimab)
– ICI (ipi/nivo) .
We need to move to a default of including patients with untreated/progressive brain mets in clinical trials starting in phase 1!”
Harold J Burstein, Breast cancer specialist and professor at Dana-Farber Cancer Institute and Harvard Medical School, shared a post by Nancy Lin, on X, adding:
“The eponymous “Nancy Lin Rule” holds again for treatment of CNS metastases. The best drug ‘outside’ the CNS will also be the best drug in the CNS. And the corollary is: the best way to identify new CNS treatments is to have potent new drugs that work outside the CNS.”
More posts featuring Harold J Burstein on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023